This segment focuses on the development and commercialization of novel antibiotics to combat antimicrobial resistance. The lead product, NUZYRA (omadacycline), is a broad-spectrum antibiotic approved for community-acquired bacterial pneumonia and acute bacterial skin infections. Research and development efforts are directed towards expanding the clinical utility of omadacycline and identifying new antibacterial agents. The company employs advanced tetracycline chemistry to create innovative therapies. This segment addresses the critical need for effective treatments against resistant bacteria, improving patient outcomes and reducing the burden of infectious diseases. Future opportunities include expanding NUZYRA's indications and developing new antibiotics to address emerging threats. Paratek collaborates with government agencies and other partners to support the development and distribution of its products.

This segment is dedicated to developing and commercializing therapies for dermatological conditions, with a focus on acne vulgaris. The lead product, SEYSARA, is a tetracycline-derived treatment designed for moderate to severe acne. Research and development activities include optimizing the formulation and delivery of SEYSARA to improve efficacy and reduce side effects. The company leverages its expertise in tetracycline chemistry to create targeted therapies for skin conditions. This segment aims to provide effective and well-tolerated treatments for acne, improving patients' quality of life and self-esteem. Future opportunities include expanding the dermatology pipeline with new products and indications. Paratek collaborates with dermatologists and other healthcare professionals to advance its dermatology portfolio.